Impact of HPV vaccination with Gardasil® in Switzerland

BACKGROUND: Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomaviruses (HPV), has been offered to 11–14 year-old schoolgirls in Switzerland since 2008. To evaluate its success and its potential impact on cervical cancer screening, HPV genotypes were ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacot-Guillarmod, Martine, Pasquier, Jérôme, Greub, Gilbert, Bongiovanni, Massimo, Achtari, Chahin, Sahli, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741926/
https://www.ncbi.nlm.nih.gov/pubmed/29273004
http://dx.doi.org/10.1186/s12879-017-2867-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741926/
https://www.ncbi.nlm.nih.gov/pubmed/29273004
http://dx.doi.org/10.1186/s12879-017-2867-x

Ejemplares similares